On 10/11/2018 Thomas E Hughes, Director, bought 10,000 with an average share price of $4.77 per share and the total transaction amounting to $47,700.00.

On 2/13/2018 Adam Scott Levy, Insider, bought 9,090 with an average share price of $5.50 per share and the total transaction amounting to $49,995.00.

On 2/13/2018 Bruce Booth, Director, bought 545,454 with an average share price of $5.50 per share and the total transaction amounting to $2,999,997.00.

On 12/20/2017 Thomas E. Hughes, Director, sold 12,000 with an average share price of $8.00 per share and the total transaction amounting to $96,000.00.

On 6/22/2017 Adam Scott Levy, Insider, bought 200 with an average share price of $7.55 per share and the total transaction amounting to $1,510.00.

On 3/10/2017 Kyle Lefkoff, Director, sold 5,800 with an average share price of $14.34 per share and the total transaction amounting to $83,172.00.

On 3/8/2017 Kyle Lefkoff, Director, sold 15,000 with an average share price of $15.40 per share and the total transaction amounting to $231,000.00.

About Miragen Therapeutics Inc (NASDAQ:MGEN)Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan. The company also develops MRG-107, an inhibitor of miR-155 for treating neuronal amyotrophic lateral sclerosis, and other neurodegenerative indications, including spinal cord injury. It also develops preclinical product candidates for treating various indications, including oncology, visual pathologies, neurodegeneration, and hearing loss. Miragen Therapeutics, Inc. has a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. The company was founded in 2006 and is based in Boulder, Colorado.

POPULAR CATEGORY

Market Exclusive offers the latest financial news and analysis for selected US stocks and securities. We are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors. Our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses. Our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions.
At Market Exclusive, we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices.
Market Exclusive is not a registered investment broker/dealer. The content on this site is for informational purposes only. Additionally, the content on this site does not represent the views of Market Exclusive and is solely a representation of the authors who publish them. Before investing in any security you should do your own due diligence and consult with a registered broker or financial advisor.